Session Details

P005 Innovation in Business and Leadership in Dermatology

Fri, Aug 2, 10:00 AM - 12:00 PM
607
2 CME Available 2 Hour Parallel Practice Management
View Map

DESCRIPTION

Medicine is one of the largest Businesses in the world. Most medical training does not involve learning about this important topic. In this session Dermatologists and trainees will learn about innovation in various aspects of Business and Leadership in Medicine and Dermatology.

LEARNING OBJECTIVES

1.

Describe various innovations in business of Dermatology and Medicine

2.

Outline various practice settings for Dermatologists and Trainees and how to improve it with innovative approaches

3.

Describe innovation in leadership: “Perspectives from AAD and AMA”

SCHEDULE

5:00 PM

Innovation in running and starting a successful Dermatology Practice

Mark D. Kaufmann, MD, FAAD

5:15 PM

Innovation in running a successful Surgical Dermatology Practice

Howard Wooding Rogers, MD, PhD, FAAD

5:30 PM

Innovation in running a successful Dermatopathology practice

Tammie C. Ferringer, MD, FAAD

5:45 PM

Innovative ways to get involved with AAD Leadership

Daniel D Bennett, MD, FAAD

6:00 PM

Innovation in Teledermatology

George Han, MD, PhD, FAAD

6:15 PM

AI in dermatology

Faranak Kamangar, MD, FAAD

6:30 PM

Innovation in running a successful Pediatric Dermatology practice

Robert Sidbury, MPH, MD, FAAD

6:45 PM

Panel discussion and Q & A

SPEAKERS

Daniel D Bennett, MD, FAAD

Daniel D Bennett, MD, FAAD

Tammie C. Ferringer, MD, FAAD

Tammie C. Ferringer, MD, FAAD

Geisinger Med Center

George Han, MD, PhD, FAAD

George Han, MD, PhD, FAAD

Faranak Kamangar, MD, FAAD

Faranak Kamangar, MD, FAAD

Mark D. Kaufmann, MD, FAAD

Mark D. Kaufmann, MD, FAAD

Keyvan Nouri, MBA, MD, FAAD

Keyvan Nouri, MBA, MD, FAAD

Howard Wooding Rogers, MD, PhD, FAAD

Howard Wooding Rogers, MD, PhD, FAAD

Robert Sidbury, MPH, MD, FAAD

Robert Sidbury, MPH, MD, FAAD

SPEAKER DISCLOSURES

Daniel D Bennett, MD, FAAD

No financial relationships exist with ineligible companies.

Tammie C. Ferringer, MD, FAAD

No financial relationships exist with ineligible companies.

George Han, MD, PhD, FAAD

AbbVie – Speaker(Honoraria); Amgen – Advisory Board(Honoraria); Avillion – Investigator(Grants/Research Funding); Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Advisory Board(Honoraria); Castle Biosciences – Advisory Board(Honoraria); Celgene – Investigator(Grants/Research Funding); DermTech Inc. – Advisory Board(Honoraria); Eli Lilly and Company – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Hikma Pharmaceuticals – Speaker/Faculty Education(Honoraria); Incyte Corporation – Advisory Board(Honoraria), Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); LearnHealth/LearnSkin – Speaker/Faculty Education(Honoraria); MC2 Therapeutics – Investigator(Grants/Research Funding); Novartis Pharmaceuticals Corp. – Investigator(Grants/Research Funding); Othro Dermatologics – Advisory Board(Honoraria); Pfizer Inc. – Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Speaker(Honoraria); Sanofi – Advisory Board(Honoraria); Sanofi Genzyme – Speaker(Honoraria); Sonoma Pharmaceuticals – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Speaker(Honoraria); UCB – Advisory Board(Honoraria);

Faranak Kamangar, MD, FAAD

No financial relationships exist with ineligible companies.

Mark D. Kaufmann, MD, FAAD

Almirall – Consultant (1099 relationship)(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Avita Medical – Consultant (1099 relationship)(Fees); Biofrontera – Consultant (1099 relationship)(Fees); Dermsquared – Other(Fees); DermTech Inc. – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Incyte – Consultant (1099 relationship)(Fees); Modernizing Medicine – Consultant(Stock); MoleSafe, Inc. – Other(Stock); Novan – Consultant (1099 relationship)(Fees); Novartis – Consultant (1099 relationship)(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pelthos Therapeutics – Consultant (1099 relationship)(Fees); Rise Healthcare Tech, Inc. – Advisory Board(Stock Options); Rivera Consulting – Consultant (1099 relationship)(Fees); ROM Technologies Inc. – Consultant (1099 relationship)(Stock); Sanofi/Regeneron – Consultant (1099 relationship)(Fees); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); UCB Pharma – Consultant (1099 relationship)(Fees); Verrica Pharmaceuticals Inc – Consultant (1099 relationship)(Fees);

Keyvan Nouri, MBA, MD, FAAD

iVeena Delivery Systems-Eye Drug Delivery – Stockholder(No Compensation Received); Pfizer Inc. – Stockholder(No Compensation Received);

Howard Wooding Rogers, MD, PhD, FAAD

No financial relationships exist with ineligible companies.

Robert Sidbury, MPH, MD, FAAD

Arcutis, Inc. – Advisory Board(Honoraria); Beiersdorf, Inc. – Speaker/Faculty Education(Honoraria); Castle Biosciences – Investigator(Grants/Research Funding); Dermavant Sciences, Inc. – Advisory Board(Honoraria); Dermavent – Advisory Board(Honoraria); Eli Lilly – Advisory Board(Honoraria); Galderma Global – Consultant(Honoraria); Leo Pharma Inc – Advisory Board(Honoraria); Regeneron Pharmaceuticals, Inc. – Investigator(No Compensation Received); UCB – Investigator(Grants/Research Funding);